Tag : EGFR MUTATION

NEWS AND PERSPECTIVE

FDA approves the addition of chemotherapy to osimertinib in EGFRm advanced lung cancer
Osimertinib is a third-generation, orally administered epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) previously approved for the first-line treatment of EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).
NEWS AND PERSPECTIVE

FDA approves amivantamab + chemotherapy in NSCLC with EGFR exon 20 insertion mutations
Alterations in the epidermal growth factor receptor (EGFR) gene occur in up to 40% of non-small cell lung cancers (NSCLCs), among which exon 20 insertions are the third most common type of mutation and account for up to 12% of EGFR-mutated (EGFRm) cases.